Topic

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

New program seeks to reduce misuse and adverse reactions by simplifying prescription labels.

FDA Proposes Streamlined Medication Handouts

Dae Y. Lee is a pharmacist attorney in Frier Levitt’s life sciences department.

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.

The Consolidated Appropriations Act and PBM Transparency

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Areas of focus during phase-out include telehealth and patient access.

Preparing for the End of the COVID Health Emergency

Agency seeks added resources and new approaches to accelerate more of these promising treatments to the market.

FDA Eyes New Strategies to Spur Gene Therapy Development

The Supreme Court’s emergency action maintaining access to mifepristone fails to protect agency from future rulings that could subvert drug approval process.

Court Ruling Leaves FDA Authority in Limbo

Legal experts: Ruling on abortion pill could spur challenges involving other authorized medical products.

FDA Regulatory Authority Under Attack

Taking stock as the Orphan Drug Act hits its 40-year anniversary.

Kudos and Hurdles for Industry, FDA in Tackling Rare Diseases

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

At Pharma USA 2023, Peter Marks, MD, PhD and director of CBER described FDA and public/private partnerships working toward scalable manufacturing approaches to address commercial viability and global access for cell and gene therapies

CGT: Collaborate to Scale

Impact areas that will be closely watched during phase-out include drug testing and authorization, telehealth, and patient access.

FDA, Industry Prepare for End to COVID Health Emergency

Region’s diversity plays against efforts to curtail counterfeit drugs.